The Woodlands, TX (PRWEB) December 15, 2014
A leading contract manufacturer of clinical-grade plasmid DNA, VGXI announced today the expansion of its state-of-the-art cGMP manufacturing facility. The expansion will include an additional 3,000 square feet of space, with the primary purpose of building a dedicated, small scale cGMP production plant. Once operational, the second facility will provide greater manufacturing capacity and allow multiple client campaigns to run in parallel. As part of the overall expansion plan, the team at VGXI has already begun installation and preparation of a new 40L fermentor to add to its existing fermentation equipment.
“This is an exciting time for the field of gene therapy and DNA Vaccines. As these technologies mature, more and more companies are moving their products into clinical trials and closer to regulatory approval. The use of an experienced manufacturer to supply high quality and purity plasmid DNA at multiple scales will be an important factor in ensuring both safety and efficacy of these products.” – Christy Franco, Business Development Manager at VGXI
Having earned the Vaccine Industry Excellence Award for best CMO in both 2013 and 2014, VGXI is already positioned as an industry leader. The 3,000 sq ft expansion will enable the company to continue to meet the growing global demand for DNA-based pharmaceuticals.
ABOUT VGXI, INC.
With over 15 years of experience, VGXI Inc. is a leading provider of plasmid DNA manufacturing and development services for DNA vaccine and gene therapy research. The company has an outstanding track record of success in manufacturing plasmid products under GMP conditions for clinical trials in the US, EU, Asia and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. VGXI is a wholly- owned subsidiary CMO of GeneOne Life Science, Inc. (KRX:011000)
Cautionary Factors That May Affect Future Results – Materials in this Website contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements do not relate strictly to historical or current facts and can therefore be identified as such. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on this Web site as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.
Author: Christy Franco, PhD